Ralph Hb Benedict
Overview
Explore the profile of Ralph Hb Benedict including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
58
Citations
1245
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Reeves J, Weinstock Z, Zivadinov R, Dwyer M, Bergsland N, Salman F, et al.
Mult Scler
. 2023 May;
29(8):1033-1038.
PMID: 37161349
Background: Paramagnetic rim lesions (PRL) may be linked to relapse risk of people with relapsing-remitting multiple sclerosis (pwRRMS). Objective: To determine the relationship between presence of PRL lesions and cognitive...
12.
Jakimovski D, Silva D, Bergsland N, Dwyer M, Weinstock-Guttman B, Benedict R, et al.
Mult Scler Relat Disord
. 2023 Apr;
74:104708.
PMID: 37084495
Background: The effect of disease modifying therapies (DMTs) on brain atrophy in persons with multiple sclerosis (pwMS) is typically investigated in highly standardized clinical trial settings or single-center academic institutions....
13.
Fuchs T, Gillies J, Jaworski 3rd M, Wilding G, Youngs M, Weinstock-Guttman B, et al.
Mult Scler Relat Disord
. 2022 Dec;
68:104375.
PMID: 36544304
Background: The Symbol Digit Modalities Test (SDMT), the most reliable and sensitive measure of cognition in people with multiple sclerosis (PwMS), is increasingly used in clinical trials and care. Objectives:...
14.
Jakimovski D, Kavak K, Longbrake E, Levit E, Perrone C, Bar-Or A, et al.
Mult Scler Relat Disord
. 2022 Oct;
68:104235.
PMID: 36283322
Background And Objective: The COVID-19 pandemic negatively impacted the well-being of persons with neuroinflammatory diseases (pwNID). Identifying factors that influence the response to challenging conditions could guide supportive care. Methods:...
15.
Zivadinov R, Jakimovski D, Ramanathan M, Benedict R, Bergsland N, Dwyer M, et al.
Mult Scler Relat Disord
. 2022 Aug;
67:104094.
PMID: 35964555
Background: Ocrelizumab is an effective treatment for relapsing and primary-progressive multiple sclerosis (MS). However, the effect of ocrelizumab on leptomeningeal (LM) inflammation is unknown. Objective: To investigate whether ocrelizumab reduces...
16.
17.
Cree B, Arnold D, Fox R, Gold R, Vermersch P, Benedict R, et al.
Mult Scler
. 2022 Apr;
28(10):1591-1605.
PMID: 35380078
Background: Siponimod significantly reduced the risk of confirmed disability progression (CDP), worsening in cognitive processing speed (CPS), relapses, and magnetic resonance imaging (MRI) measures of brain atrophy and inflammation versus...
18.
Arnold D, Piani-Meier D, Bar-Or A, Benedict R, Cree B, Giovannoni G, et al.
Mult Scler
. 2022 Mar;
28(10):1526-1540.
PMID: 35261318
Background: Magnetic resonance imaging (MRI) measurements of gray matter (GM) atrophy and magnetization transfer ratio (MTR; correlate of myelination) may provide better insights than conventional MRI regarding brain tissue integrity/myelination...
19.
Weinstock Z, Morrow S, Conway D, Fuchs T, Wojcik C, Unverdi M, et al.
Mult Scler
. 2021 Oct;
28(7):1101-1111.
PMID: 34612114
Background: The Symbol Digit Modalities Test (SDMT) is increasingly utilized in clinical trials. A SDMT score change of 4 points is considered clinically important, based on association with employment anchors....
20.
Wojcik C, Jaworski 3rd M, Dwyer M, Youngs M, Unverdi M, Weinstock-Guttman B, et al.
Mult Scler
. 2021 Sep;
28(3):487-491.
PMID: 34498512
Background: Previous studies have established benchmarks of clinically meaningful decline on neuropsychological tests. However, little is known about meaningful testing benchmarks based on gains in function. Objective: Investigate neuropsychological changes...